Index

Abus de droit, 317
Abuse of IP rights, 316, 330
abuse of patents, 155, 288
Article 5A(2) of the Paris Convention
failure to work, 317
strategic litigation or sham litigation, 318
Abuse of rights, 316
Access to essential goods, 281
Access to ESTs, 82, 97, 110, 121, 148, 234, 254, 304, 307, 313, 354, 359
Access to know-how, 316
Access to technology, 49, 63, 78, 132, 206, 285, 321
ACTA, 72
Ad Hoc Working Group on Long-Term Co-operative Action, 104
African Group, 220, 261
African Group, 220, 261
Agenda 21, 14, 97, 105, 283
ALBA Countries, 100
Ambiguous obligations and exceptions, 210
Andean Community, 252
Anell Draft, 324
Anglo-American legal tradition, 31
Annex I countries, 90
Annex II countries, 82, 91, 100
Anti-competitive practices, 143–55, 230, 279, 281, 293, 296, 301, 312–13, 328, 336, 358, 339, 343, 345
blockage, 145–48
block market entry, 145
strategic patenting, 145
contractual restraints, 311
exclusive grant back, 153
export restrictions, 153, 335
grant-back provisions, 335
high licensing fees, 148–50
limitation to follow-on innovation, 335
limiting follow-on innovation, 153
Mexico – Telecoms (2004), 333
refusal to license, 150–53
unilateral conduct, 311
Anti-patent proposal, 241
Appellate Body, 161, 164, 167, 171–72, 174, 255
Article 2.1(g) of VCLT, 184
Article 31 of VCLT, 84, 169–70, 192, 268, 297, 303, 308, 344, 355, 360
General Rule of Interpretation, 162
the principle of good faith, 164
Article 31(1) of VCLT
context, 174–76
object and purpose, 172–73
ordinary meaning, 170–72
the principle of good faith, 164–70
Article 31(2) of VCLT
calendar, 175
Article 31(3)(a) of VCLT, 215
subsequent agreement, 177–79
Article 31(3)(b) of VCLT
negotiating history, 181
subsequent practice, 179–81
Article 31(3)(c) of VCLT, 229
principle of systemic integration, 182
relevant rules of international law, 181–86
US – Anti-Dumping and Countervailing Duties (2011), 183
Article 32 of VCLT, 162–63
supplementary means of interpretation, 174, 186–92
411
Index

Articles 31 and 32 of VCLT, 231, 261, 313, 350
Authoritative interpretation, 261, 328

Balance
between competing public policy interests, 257
between creating incentives for innovation and ensuring access to new technologies, 60
between intellectual property rights and other important socio-economic objectives, 207
between IP protection and competition, 322
between patent policy and the policy favouring free competition, 118
between the private rights and the objective of public policy, 205
between the protection of IPRs and access to technologies, 156
between the protection of the exclusive rights and the social goals of the wider transfer of ESTs, 156
between the public and private spheres, 24
between traditional development-oriented international treaties and emerging environmental norms, 200

Balance and weigh, 202
Balanced and pro-competitive interpretation, 346
Balanced and tailored interpretation of IP-related obligations, 214, 351

Bali Climate Summit, 358
Bangladesh, 307

BASIC Group, 99
Beine Convention, 66, 190
Article 9.2, 260

Blanket exclusions of ESTs, 309

Bolar exemption, 262, 267
Bona fide, 287–88, 301, 308, 352
Brazil, 33, 37, 117, 275, 305
Brazil – Retreaded Tyres (2007), 210, 235
Brazil's 1996 Industrial Property Law, 239
Brazil's HIV/AIDS program, 239
Brazil's 1996 Industrial Property Law Article 68(1), 285

BRIC, 39, 41, 45
Brundtland Report, 198
Brussels Ministerial Text, 324
Canada

Canada’s Patent Act, 262
Cancun
Cancun Agreement, 94, 105
Cancun meeting, 105

CBD, 49, 79
Article 16, 84

CBDR, 79–82
a political necessity, 81
Article 3.1 of the UNFCCC, 80
common responsibilities, 80
differentiated responsibilities, 80
historical contribution to problems, 81
Principle 7 of the Rio Declaration, 79
Chairman’s Draft Text of 23 November 1990, 334

Chapter 34 of Agenda 21, 12, 97
Characteristics of technologies, 121
Chatham House Report, 35, 157
China, 12, 20, 35, 35–57, 97, 157, 152, 154
China – Publications and Audiovisual Products (2000), 173
China – Rare Earths (2014), 201
China – Raw Materials (2012), 105
Circumstances of the conclusion, 174, 189–90
EC – Chicken Cuts (2005), 173

CEU, 274, 316, 340
IMS (2004), 341
Magill (1995), 340
Microsoft (2007), 341
Clean Development Mechanism, 90–91
Clean energy technologies, 36, 38, 126–27, 153, 201
Climate change, 234
common concern of mankind, 1, 211
major contributor to, 17
national emergency or other circumstances of extreme urgency, 360
resolution of 43/53 of 1988, 1
the defining challenge of our era, 1
Climate change adaptation technologies, 114
Climate change mitigation, 15, 232, 290, 301, 350
Climate change mitigation technologies, 38, 306
Climate change negotiations, 148, 241, 256, 348–49
Climate Technology Centre and Network, 94–95

© in this web service Cambridge University Press
www.cambridge.org
Combating climate change

immediate and urgent global priority, 302

Commitments to transfer ESTs, 351

Common concern of mankind, 1, 232, 235, 301, 335

Common intentions of the parties, 189, 191, 214

Commonwealoth, 272

Competing public values, 213

Competition law, 283, 312–13, 321–22, 330, 332, 336

Competition policy, 277, 312–13, 322

Competition threats, 152

Competition-related flexibilities, 313, 354–55

Competition-related provisions, 5, 160, 313, 343, 354

Competitive advantage, 23, 36, 125, 140, 144, 146–47, 153, 311, 325, 349

Compulsory licences, 227, 259, 278–83, 287, 299, 351

adequate remuneration, 279

level of remuneration, 294

taking into account, 294

adequate remuneration (Article 31(b)), 293

appropriateness and effectiveness, 305

Article 31 of the TRIPS Agreement, 281

Article 31(1), 313–37

Article 5(2)(a) of the Paris Convention, 279

circumstances of extreme urgency, 224

conditions, 303

conditions and procedural requirements, 291–97

independent review, 293

on its individual merits, 291

prior negotiation requirement, 292

environmental protection, 260

grounds, 282–83

lack of local working, 301

legitimate interest of the compulsory licensee, 295

level of compensation, 303

national emergency, 224

climate change, 302

non-working of the invention, 286

on its individual merits, 303

on the grounds of mitigating climate change, 301

predominantly for domestic use, 306

predominantly for the supply of the domestic market, 266

protection of legitimate interest, 295

refusal to license, 345

scope and duration, 205

non-assignable, 296

non-exclusive, 296

several goals, 279

threat of, 300

threat thereof, 304

UK Patents Act, 284

Compulsory licensing, 54, 99, 102, 303–4, 360

Conference of the Parties, 84

COP-1, 91–93

COP-16, 94

COP-3, 87

COP-7, 90, 92

COP-8, 82

Consent, 18, 73, 113, 116, 215, 257, 271, 278, 281

Consistency requirement

Articles 31 and 40, 323

Articles 7 and 8.1, 323

Articles 8.2 and 40.2, 322–24

basic balance of rights and obligations, 211

divergent interpretations, 210

Preamble, 323

Constructive ambiguity, 160

Consumer protection, 277

Consumer welfare, 341

Contemporary concerns of the community of nations, 231

US – Shrimp (1998), 226

Contemporary international concern, 223

Context, 174–76

“may shed light” on the meaning, 174

agreement, 175

US – Section 110 (5) Copyright Act (2000), 175

annexes of treaties, 174

Article 31(1) of VCLT, 174

Article 31(2) of VCLT, 174

Canada – Pharmaceutical Patents (2000), 176

Korea – Dairy Safeguards (1999), 174

preamble, 174

related to the treaty, 175

EC – Chicken Cuts (2005), 175

US – Section 110 (5) Copyright Act (2000), 175

Contextual elements, 214

Article 31(1) of the VCLT, 176


obligatory character, 176

Copenhagen, 4, 94, 98, 103

Copenhagen Accord, 105

Copenhagen Climate Summit, 98

Copenhagen negotiations, 104
414

Index

Council for TRIPS, 45, 67–68, 76, 78, 297
Court of First Instance of the EU
Microsoft v. Commission, 332
Covered agreements, 161, 167, 193
Customary rules of interpretation of public international law, 102, 236, 372
Articles 31 and 32 of VCLT, 161
Customs territories, 184
Danish Text, 104
De jure discrimination, 112
Decision
Decision of 30 August 2003, 224
Decision of the Ministerial Conference on Implementation-Related Issues and Concerns, 76
Decision on Trade and Environment, 105
Declaration on Intellectual Property and Climate Change, 359
Declaration on Patents Protection: Regulatory Sovereignty under TRIPS, 204
Developed countries, 2, 18, 28, 38, 45, 49, 54, 60, 71, 75, 81, 86, 97, 101, 160
Development & Employment Alliance, 101
Development Agenda, 72
Development and technological objectives, 205
Differential pricing, 277
Differential treatment, 288
ESTs, 308
fast track mechanisms, 246
Disclosure requirement, 284
Dispute settlement panels, 255, 286
Doha Declaration, 179, 192, 206, 228, 256, 276, 281, 283, 289, 296, 298–99, 302, 308, 351, 358
access to medicines for all, 223
exhaustion regime, 224
implications, 224–26
Paragraph 4, 211, 216, 288
Paragraph 5(b), 287
Paragraph 6, 224, 297
insufficient or no manufacturing capacities, 224
political obstacle, 225
precedent, 226
public health, 221
right to grant compulsory licences, 224
right to protect public health, 223
subsequent agreement, 215–19
Doha Ministerial Conference, 75, 289
Doha Ministerial Declaration, 166, 202
Doha-type Declaration on Intellectual Property Rights and Climate Change, 5, 7, 347
Domestic implementation, 205
Dominant position, 332, 339–40
DSU, 160
Article 3.2, 160, 231
customary rules of interpretation of public international law, 161
Durban, 105
Durban Agreement, 105
East Asian countries, 252
EC
EC – Approval and Marketing of Biotech Products (2006), 184, 294
EC – Bananas III (Ecuador) (Article 22.5 – EC), 85
EC – Chicken Cuts (2005), 173–75, 179–80
EC – Computer Equipment (1998), 169, 190
EC – Hormones (1996), 266
EC and certain member States – Large Civil Aircraft (2011), 185
EC Treaty
Article 52, 316
Economic development, social development and environmental protection, 199
Economic, social and environmental concerns, 202–3
Ecuador, 235, 303
EGTT, 92, 94
Emerging countries, 33–34, 36–38, 99, 138, 143, 152, 159, 244, 347
Enabling environment, 272, 338
Enforcement of IPRs, 118–19
civil sanctions, 114
criminal penalties, 114
effective domestic enforcement, 118
effective remedies, 119
Part III of TRIPS, 119
Environmental protection, 214, 250, 255, 308, 350
Equity, 80, 128, 260, 316
Erga omnes, 116
Index

Essential facility doctrine, 339–40, 343
“new product” criterion, 341
exceptional circumstances test, 340
IMS (2004), 341
indispensable, 340
Magill (1995), 340
Microsoft (2007), 341
secondary market, 340
US jurisprudence, 340
Essential patents, 567
EST transfer commitments, 79, 87, 230, 308
ESTs
bio-fuels, 112, 117, 240
carbon capture and storage, 125
carbon storage, 241
clean energy technologies, 25, 126, 138
defining, 13–15
Agenda 21 definition, 14
Examples, 15
UNFCCC, 15
differentiated IP regimes, 245
global public goods, 25–26
international externality effects, 25
key features, 14
low carbon technologies, 137
protected by different types of IPRs, 149
PV solar, 125
renewable energy technologies, 113, 125–26, 241
Solar PV, 137
special treatment for ESTs, 121
system technologies, 307
wind energy technologies, 127, 137, 147, 149
EU, 244
EU position for the Copenhagen Climate Conference, 103
European Commission Decision, 332
Article 56, 248
European Court of Human Rights, 182
Evergreening, 242
Exceptions and limitations to patents, 227
Exceptions to patent rights
Article 30 of the TRIPS Agreement, 259
Article 9.2 of the Berne Convention, 260
authorisation, 259
Canada – Pharmaceutical Patents (2000), 259, 260, 271
limited, 260
non-commercial experimental use, 261
prior use, 271
prior use rights, 261
private use, 271
private, non-commercial purposes, 271
research or an experimental use exception, 271
research or experimental purposes, 271
safe harbour, 259
scientific use, 271
scope, 260
statutory exceptions, 261
taking account of the legitimate interests of third parties, 260
technology-neutral, 244
three-step test, 260
unreasonably conflict with the normal exploitation, 260
unreasonably prejudice the legitimate interests of the patent owner, 260
use aboard vessels temporarily, 261
Exclusive effects, 122, 140, 156, 309, 350, 353
Exclusive rights, 256, 279, 311, 337
scope, 269
Exhaustible natural resources, 203
Exhaustion of patent rights, 273–76
Article 6 of TRIPS, 275
Doha Declaration, 276
Footnote 6 of TRIPS, 275
international exhaustion of patent rights, 275
national exhaustion of patent rights, 275
regional exhaustion of rights, 274
Experimental use exceptions, 273
Expresio unius est exclusio alterius, 241
Externalities, 26–28
environmental externalities of ESTs, 127
negative environmental externalities, 125
Failure to work, 31, 279, 285–88, 309, 354
FDI, 18–20, 48, 71, 122, 133–36
Financial mechanism, 84, 106
First sale. See exhaustion of patent rights
Follow-on innovation, 140–41, 153–55, 249–50, 308, 339, 349, 352, 366
Fossil fuels, 15, 25, 126
FRAND, 366, 368
Free-riding, 31, 152
Free-riding, 25, 45, 70, 77, 123, 155, 341, 349
FTAs, 4, 98

<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>G77, 54, 58, 99</td>
</tr>
<tr>
<td>GATS, 255</td>
</tr>
<tr>
<td>Article XIV, 209</td>
</tr>
<tr>
<td>GATT, 55, 59, 61, 193–94, 204, 231, 234, 240, 255, 275</td>
</tr>
<tr>
<td>Article XX, 208, 210</td>
</tr>
<tr>
<td>Brazil – Retreaded Tyres (2007), 255</td>
</tr>
<tr>
<td>Article XX(b), 208</td>
</tr>
<tr>
<td>necessary, 208</td>
</tr>
<tr>
<td>otherwise inconsistent, 208</td>
</tr>
<tr>
<td>Article XX(d), 61, 69</td>
</tr>
<tr>
<td>Article XX(g), 201</td>
</tr>
<tr>
<td>process and structure of, 69</td>
</tr>
<tr>
<td>GATT 1947, 189, 195, 204</td>
</tr>
<tr>
<td>GATT CONTRACTING PARTIES, 180</td>
</tr>
<tr>
<td>GATT negotiations, 62</td>
</tr>
<tr>
<td>GEF, 84</td>
</tr>
<tr>
<td>General Council, 217, 224, 275</td>
</tr>
<tr>
<td>General Electric, 101, 146</td>
</tr>
<tr>
<td>Generalised System of Preferences (GSP), 63</td>
</tr>
<tr>
<td>Generic medicines, 146</td>
</tr>
<tr>
<td>Germany, 35–36, 44, 232</td>
</tr>
<tr>
<td>German patent law, 290</td>
</tr>
<tr>
<td>GHG-reducing technologies, 143</td>
</tr>
<tr>
<td>GHG emissions, 2, 79, 86, 94, 290, 368</td>
</tr>
<tr>
<td>Goldwind Global, 150</td>
</tr>
<tr>
<td>Good faith, 171, 288</td>
</tr>
<tr>
<td>Green Climate Fund, 367</td>
</tr>
<tr>
<td>Grey-market imports. See parallel imports</td>
</tr>
<tr>
<td>Guide to the Application of the Paris Convention for the Protection of Industrial Property, 284</td>
</tr>
<tr>
<td>Guidelines for licensing IP-protected ESTs, 368</td>
</tr>
<tr>
<td>High licensing fees, 145, 148–50, 153–54, 325</td>
</tr>
<tr>
<td>High royalties, 47, 154, 321</td>
</tr>
<tr>
<td>High standard of patentability, 251</td>
</tr>
<tr>
<td>High technology products, 134</td>
</tr>
<tr>
<td>Human Genome Project, 141</td>
</tr>
<tr>
<td>Humanitarian or preferential licensing, 106, 367</td>
</tr>
<tr>
<td>ILC, 162–64, 166, 170–71, 174, 177–79, 185, 187, 218</td>
</tr>
<tr>
<td>Imitation, 61, 132, 142, 243</td>
</tr>
<tr>
<td>creative imitation, 23</td>
</tr>
<tr>
<td>duplicative imitation, 23</td>
</tr>
<tr>
<td>imitation based catch-up and development approach, 23</td>
</tr>
<tr>
<td>Korea, Japan, Singapore and the US, 23</td>
</tr>
<tr>
<td>imitation-based technological development path, 142</td>
</tr>
<tr>
<td>informal channels of technology transfer, 22</td>
</tr>
<tr>
<td>the legality of, 22</td>
</tr>
<tr>
<td>In dubio mitius, 294</td>
</tr>
<tr>
<td>India, 37, 97, 137, 149, 152, 275</td>
</tr>
<tr>
<td>India – Patent Protection (1997), 161</td>
</tr>
<tr>
<td>India – Patents (US) (1997), 169</td>
</tr>
<tr>
<td>Indigenous innovation, 143</td>
</tr>
<tr>
<td>Industry characteristics, 243</td>
</tr>
<tr>
<td>Information asymmetries, 26, 28, 368</td>
</tr>
<tr>
<td>Innovation and transfer of technologies</td>
</tr>
<tr>
<td>a central theme of, 2</td>
</tr>
<tr>
<td>global response to climate change, 1</td>
</tr>
<tr>
<td>in the negotiations, 2</td>
</tr>
<tr>
<td>part of the solution to climate change, 11–13</td>
</tr>
<tr>
<td>Provisions for, 1</td>
</tr>
<tr>
<td>to limit developing countries’ greenhouse gas (GHG) emissions, 1</td>
</tr>
<tr>
<td>Innovation of ESTs</td>
</tr>
<tr>
<td>high concentration, 38–39</td>
</tr>
<tr>
<td>highly concentrated, 3, 32</td>
</tr>
<tr>
<td>Chatham House study, 35</td>
</tr>
<tr>
<td>Dechezlepretre et al. (2011), 33</td>
</tr>
<tr>
<td>UNEP, EPO and ICTSD (2010), 36</td>
</tr>
<tr>
<td>Insufficient manufacturing capacities, 296, 306, 310, 356</td>
</tr>
<tr>
<td>Integral part, 116, 161, 168, 176, 198, 216</td>
</tr>
<tr>
<td>Intellectual property rights (IPRs)</td>
</tr>
<tr>
<td>a fairly high protection of, 2</td>
</tr>
<tr>
<td>exclusive rights, 29</td>
</tr>
<tr>
<td>exclusivity, 148</td>
</tr>
<tr>
<td>expansion of, 32</td>
</tr>
<tr>
<td>ipsis prohibendi, 139</td>
</tr>
<tr>
<td>justification, 29–32</td>
</tr>
<tr>
<td>incentives to create, 32</td>
</tr>
<tr>
<td>rights-based property, 29</td>
</tr>
<tr>
<td>utilitarian, 29</td>
</tr>
<tr>
<td>legitimate barrier to free trade, 62</td>
</tr>
<tr>
<td>policy interventions, 28</td>
</tr>
<tr>
<td>private rights, 119</td>
</tr>
<tr>
<td>strengthening of, 43</td>
</tr>
<tr>
<td>revenue transfer, 45</td>
</tr>
<tr>
<td>to incentivize innovation, 2</td>
</tr>
<tr>
<td>International Court of Justice</td>
</tr>
<tr>
<td>Aerial Incident Case (1959), 165</td>
</tr>
<tr>
<td>Gabčíkovo-Nagymaros Project case, 199</td>
</tr>
<tr>
<td>Land, Island and Maritime Frontier Dispute (1992), 171</td>
</tr>
</tbody>
</table>
Peace Treaties with Bulgaria, Hungary and Romania (1956), 167
South West Africa Cases (1962), 172
International Exhibition of Inventions in Vienna, 30
International IP conventions, 68, 77, 118
International transfer of ESTs
empirical study, 38
literature review, 33–38
rarely transferred to developing countries, 33
Invent around, 122, 131, 140, 272, 309, 353
Inventing around, 272
Invention, 246
dictionary meaning, 246
direct technical result, 247
genuine inventions, 250
minor/incremental innovations, 250
related to public health and nutrition, 249
Inventions pertaining to ESTs, 240, 246, 250, 253
IPCC, 35, 37
IPCC, 1, 127
4th Assessment Report, 92
Report (2014), 143
Special Report on Technology Transfer, 11
IPR-related anti-competitive and abusive practices, 313
James Watt, 141
Japan, 20, 35–36, 39, 72, 141, 244
Japan – Alcoholic Beverages (1996), 162, 173, 180, 187
Johannesburg Declaration, 198
Judicial restraint, 170
Know-how, 2, 11, 14, 20, 26, 85, 84, 90, 118, 131, 306, 310, 361
Korea, 20, 35–36, 72, 142, 152
Korea – Dairy Safeguards (1999), 168, 174
Korea – Various Measures on Beef (2003), 210
Kyoto Protocol, 87–91, 96, 127, 145
Article 10, 90
Article 10(c), 88
Article 11.2, 88
Article 12, 90
Article 13.4, 87
enabling environment, 88
first commitment period, 87
legally binding emission reduction obligation, 87
the role of the private sector, 87
LDCs, 2, 38, 45, 68, 74, 76, 99, 155, 234, 367, 368
Legitimate interest, 131, 272
Legitimate interests, 213, 257, 269, 295
Canada – Pharmaceutical Patents (2000), 268
of third parties, 270, 273
Level of compensation, 294–95, 308, 343
Level of the technological development, 121
License, 35–36, 89, 152, 206, 343, 358
Licensing, 135
Licensing agreement, 37, 47, 150, 154, 320, 335
Licensing practices, 50, 138, 143, 320, 326, 328, 330, 335, 365
Lima Draft, 105
Limitations or exceptions, 257, 309, 353
the art of the policy balance, 257
Limited exception, 266–67
Canada – Pharmaceutical Patents (2000), 262
EC – Hormones (1998), 266
Local working requirements, 239, 282–89
Brazil
local manufacture requirement, 286
Canada – Pharmaceutical Patents (2000), 287
definition, 284
importation, 285
legality of, 286
legality of production-based, 286
local production, 285
Low standards of patentability, 250–51
low-quality EST patents, 251
Low-quality patents, 317–18, 252, 308, 352
Mandatory minimum patent standards, 234
Manifestly absurd or unreasonable, 162, 165, 187
Market dominance, 146
Market exclusivity, 113, 267
Market failure, 26, 127
externalities, 27
information asymmetry, 27
market power, 28
Market power, 24, 28, 75, 133, 139, 148, 154
Marrakesh Agreement, 161, 168, 192, 194–96, 201, 203, 207, 216, 231, 350
Article IX, 216
authoritative interpretation, 217
implied recommendation, 217
recommendation by the Council, 217
Marrakesh Agreement (cont.)
Article XVI:3, 192
object and purpose, 193
Preamble, 193–94, 226, 270
US – Shrimp (1998), 193
Max Planck Declaration on Patents Protection, 192, 235–36
Max Planck Institute for Innovation and Competition, 192
MEAs, 60, 78–79, 87, 108, 186
Measures to protect public health, 223
MFN, 65, 67, 112, 275–76
Minimum IPR protection standards, 344, 350, 355
Minimum IPR standards, 98, 110
‘Berne-plus’ or ‘Paris-plus’, 67
Article 1.1 of TRIPS, 66
commitments, 65–69
concerns, 120
controversy over the effect of, 119–21
effects on technology transfer, 120
enforcement of IPRs, 118–19
implications, 69–74
mandatory treaty obligation, 72
patent protection, 11–14
protection of trade secrets, 114–18
regulatory “floor”, 72
reinforced the power of private parties, 120
the effect on innovation and technology transfer, 121
Minimum standards for IP protection and enforcement. See Minimum IPR standards
Ministerial Conference, 215–16, 218, 228
Ministerial Declaration, 179, 215, 226
Doha Ministerial Declaration, 212
Ministerial Declaration for climate change, 232, 351
Punta del Este Declaration, 62, 204
MNCs, 48, 52, 60, 134, 144, 153–54, 311, 325, 349, 368
Monopoly, 63, 117, 125, 139, 146, 148, 154, 250, 252, 339
Montréal Protocol, 79, 97, 149, 151
Mutually reinforcing, 163, 201
Mutually satisfactory solution, 239
Mutually supportive, 202
Napoleonic Code, 30
National development strategies, 233
National emergency, 224, 281, 283, 292, 302, 353, 360
National emergency or other circumstances of extreme urgency, 302
National patent laws, 51, 247, 271, 279, 283–84
National security, 282
National treatment, 65, 67, 112, 233, 275–76
Necessity requirement
Article XX of the GATT, 209
Brazil – Retreaded Tyres (2007), 210
Korea – Various Measures on Beef (2003), 210
weighing and balancing, 210
New Delhi Declaration of Principles of International Law Relating to Sustainable Development, 108
NGOs, 16, 239
No patents proposal, 100
Non-discrimination clause, 112, 237–39
Article 27.1, 237
availability of patents, 238
bona fide exceptions, 245
Canada – Pharmaceutical Patents (2000), 243, 245
certain product areas, 245
differential treatment, 240
differentiate, 243
discrimination, 242
enjoyment of patent rights, 238
ESTs, 240
differential treatment, 241
field of technology, 241
function of the technology, 241
importation, 239
imported and locally produced products, 239
local working requirements, 239
non-discrimination as to the field of technology, 239–46
patent-specific, 237
place of invention, 238
scope of application, 238
structural effect, 244
technological neutrality principle, 239
unjustified differential treatment, 243
Non-discriminatory, 50, 65, 69, 195, 202, 275, 287, 367
Non-patentability, 352
contributes to protecting ordre public and morality, 253
morality, 253
Index
necessity test, 255
ordre public, 253
prohibit commercial exploitation, 254
Non-trade concerns, 232, 350
Non-trade-related concerns, 195
Non-WTO norms, 256, 308, 352
Non-WTO treaties, 185
Normal exploitation, 113, 259–61, 265, 267–68, 273
Canada – Pharmaceutical Patents (2000), 113
not unreasonably, 268
North-South, 3, 55, 64
Nuclear energy, 126

Object and purpose, 66, 85, 161, 163, 172–73, 204
Article 31(1) of the VCLT, 172
EC – Chicken Cuts (2005), 173
from the text of the treaty, 173
Japan – Alcoholic Beverages (1996)
not as an independent basis for interpretation, 173
of particular treaty’s provisions, 173
of the entire treaty, 173
preamble, 173
Object and purpose of the treaty, 172–73, 192, 261
Objective of sustainable development, 193–97, 201, 203
2001 Doha Ministerial Declaration, 196
OECD countries, 33–35, 39, 42–43
One-size-fits-all, 356, 243
OPEC, 106
Open-textured, 231–32, 254, 350–51
Ordinary meaning, 85, 161, 170–72, 174, 203, 231, 261, 288, 310, 323, 350
Article 31(1) of the VCLT, 170
dictionary definitions, 171
not dispositive, 171
essence of the textual approach, 170
fully qualified, 172
in its context and in light of the object and purpose of the treaty, 171
terms of the treaty, 170
Ordre public, 253–55, 308, 353
environmental protection, 253
to avoid serious prejudice to the environment, 254
Ozone-friendly technologies, 97, 148, 151–52

Pacta sunt servanda, 164
Paragraph 6 system, 298, 299, 304
Decision of 30 August 2003, 298
insufficient manufacturing capacity, 298
Rwanda, 299
waivers, 298
adequate remuneration, 299
Parallel imports, 226, 229, 274–77, 309, 353
international exhaustion of rights, 276
practicability and feasibility, 276–77
Paris Agreement, 2, 94–96, 106
Article 10.4, 95
Paris Climate Change Conference, 94
Paris Convention, 50–51, 66, 111, 120, 190, 216–17, 279, 284
Article 5(3)(2)
failure to work, 284, 287
Article 5A, 54, 297
Article 5(2), 279, 297
demand for the revision of, 51
the Stockholm Act (1967) of, 55
Patent abuse, 47, 52, 209, 298
Patent applications, 36, 50, 111, 126, 145, 308, 352
EST, 39
fast-track mechanisms, 246
Patent blockage, 145, 147, 154
effects of, 147
patent clusters, 145
patent litigation, 147–48
patent thickets, 145
the tragedy of anti-commons, 147
Patent boom, 126, 145
Patent claim, 131, 272, 309, 353
Patent disclosure, 36, 130–32, 155, 272, 349
Patent disclosure requirement
“social contract” theory, 128
Article 29.1 of the TRIPS Agreement, 128
best mode requirement, 129
effectiveness, 130
enabling requirement, 131
sufficiency of disclosure, 129
Patent information, 129, 241
databases, 130
role of, 132
use for experimental purposes, 131
Patent infringement, 147
Index

Policy space, 73, 195, 210, 214, 233, 303, 313, 323, 350
Positive integration, 69
Post-Kyoto climate negotiations, 304
Post-Kyoto climate regime, 91
Preamble, 193, 293, 328
Preparatory work, 174, 188–90
US – Carbon Steel (2002), 189
Principle of effectiveness, 166–68, 197, 263–64
Principle of equity, 80, 128
Principle of good faith, 164–70, 317
Article 31(1) of the VCLT, 162
reasonableness, 165
the principle of effectiveness, 166–68
as a whole, 168
Canada – Pharmaceutical Patents (2000), 167
harmoniously, 168
Korea – Dairy Safeguards (1999), 168
the principle of the protection of legitimate expectations, 166, 168–70
common intentions of the parties, 169
EC – Computer Equipment (1998), 169
India – Patents (US) (1997), 169
US – Underwear (1997), 169
ut res magis valeat quam pereat, 166
Principle of integration, 199, 202
Gabčíkovo-Nagymaros Project (1997), 200
Iron Rhine case (2005), 201
Johannesburg Declaration on Sustainable Development, 199
New Delhi Declaration, 199
Rio Declaration, 198
Kio+20 outcome document, 199
US – Shrimp (1998), 201
Principle of reconciliation, 200
Principle of sustainable development, 198, 200–1, 203
Principle of systemic integration, 185
Bankovic v. Belgium and others (2001), 182
coherence and meaningfulness, 182
US – Gasoline (1996), 182
US – Shrimp (1998), 182
Prior art, 247
Prior negotiations, 303, 343
Private rights, 64, 156, 205
Private sector, 88, 96, 103, 125, 144, 154, 160, 346, 365, 367
Patent misuse
mandatory package licensing, 318
price discrimination, 318
refusal to license, 318
resale price maintenance, 318
tying, 318
Patent office, 148, 252, 308, 352
Patent pools, 105–6
Patent rights
Article 28.1 of TRIPS, 113
limits, 256–58
qualify and limit, 235
right of importation, 113
Patent term, 73, 113, 131, 269
Patent thickets, 115, 146
general obligation of, 112
Patentability requirements, 234, 236, 246–49, 252, 352
all fields of technologies, 237
an inventive step, 248
Article 27 of the TRIPS Agreement, 236
capable of industrial application, 247
first sentence of Article 27.1, 246
non-obvious, 248
a person skilled in the art, 248
non-obviousness, 148
novelty requirement, 247
useful, 249
Patentable subject matter, 7, 73–74, 159, 235–36
blanket exclusions, 112
Patented process, 113, 278, 284, 286
Patent-related flexibilities, 6, 231, 235–36, 307–8, 310, 350, 352, 359
Patent-sensitive industries, 125
PATSTAT, 33, 128
PCT, 38, 111, 146
Per se, 170, 199, 334
Permanent Court of International Justice, 166
Compe tence of the ILO in regard to International Regulation of the Conditions of the Labour of Persons Employed in Agriculture, 166
Permissible exclusion
Article 27.2 of TRIPS, 253–56
Permissive, 257
Pro-competition provisions, 74, 231
Protect public health, 207, 211, 216, 221, 223, 226
Protection of the environment, 195, 200, 202
Public domain, 31, 72, 88, 100, 117, 123, 125, 249–51, 352
Public good, 25, 29, 208
appropriability problem, 26
free ride, 25
non-excludable, 25
non-rival, 25
Public goods, 25–27, 31, 296
concept, 208–9
Public interests, 121, 282, 293, 341
Public order. See ordre public
Public policies, 211, 289
Public policy goals
mitigating climate change, 122
Public policy objectives, 194, 209, 213, 226, 232–34, 298, 351
Quality of patent. See patent quality
R&D investment, 25, 31, 40–41, 123, 125
Reasonable, 319
reasonable commercial terms, 151, 153, 292
reasonable terms, 53, 325
Reasonableness, 368
Reconcile and integrate, 203
Reconciling, 5, 160, 201, 203, 346
Refusal to deal, 140, 152
Refusal to license, 141, 144–45, 150–53, 321, 339, 341
Refuse to deal, 70, 154, 302, 309, 354
Refuse to license, 150, 153, 311, 339, 341–42, 349, 368
Regulation governing international technology transfer
market-based development model, 47
NIEO Model
revision of the Paris Convention, 48
TOT Code, 48
Regulatory discretion, 276, 287, 313
Regulatory flexibility, 237
Regulatory review exception. See Bolar exemption
Regulatory sovereignty, 225, 322, 344, 359
Relevant market, 330, 333–34, 337, 339–40, 368
Relevant rules of international law, 5, 185, 214–15, 232, 351
applicable in the relations between the parties, 229
Article 31(3)(c) of the VCLT, 181–86
Article 38(1) of the Statue of the International Court of Justice, 183
Article 4.5 of the UNFCCC, 229
parties
a subset of all the parties, 186
EC and certain member States – Large Civil Aircraft (2011), 185
the parties to the dispute, 185
relevant, 186
Report of the Energy and Resources Institute, 149
Restrictive practices, 47, 52, 57–58, 319, 334
Reverse engineering, 18, 23, 72, 117, 125, 142–43
legality of, 117
Right to grant compulsory licences, 224, 300, 360
Right to health, 226
Right to importation
Article 28, 276
Right to protect the environment, 360
Right to protect the public interest, 253
Right to refuse to deal, 340
Right to refuse to license, 339
Rio Declaration, 195, 198
Rio Earth Summit, 14, 49, 79, 195
Rio+20 Outcome Document, 198, 302
Role of IPRs
a double-edged sword, 155, 349
a prerequisite to transfer ESTs, 152–59
an enabling factor for innovation of ESTs, 122–32
an important factor influencing EST transfer, 157–59
context-specific, 155, 349
essential incentives for innovation and transfer of ESTs, 122
exclusive effects of IPRs, 140–43
impediment to access to medicine, 222
incentive effects on innovation of ESTs, 123–27
incentive to disclose, 29, 123, 128
incentive to innovate, 122
contingent on the characteristics of the industry, 124
Index

Role of IPRs (cont.)
incentivising effects, 241
industry- and country-specific, 123
may hinder EST transfer, 139–45
positive role, 121–32
potential anti-competitive practices, 143–55
role of patent-induced information
disclosure in innovation of ESTs, 128–32
Russia, 33, 27
Rwanda, 299
Safeguards, 63, 73, 119, 159, 219, 248, 291
SBI, 93
SBSTA, 92
SCP/35/3, 227
Second uses of patents, 252
Semiconductor technology, 280
Single Undertaking, 167–68, 174, 387
Small island developing countries (SIDCs), 357
SMEs, 252
Social and economic welfare, 159, 206–7, 210, 322
Special and differential treatment principles, 69
Special needs of developing countries, 56
Spill-over, 17
SPS Agreement, 204
Standard essential patents, 147, 332
State intervention, 304
State-of-the-art. See prior art
Statute of the International Court of Justice
Article 38(1)(d), 191
Stockpiling exception, 262
Subsequent agreement, 176–78, 214–15, 218, 226, 352
"subsequent" to, 178
agreement, 177
single common act, 178
US – Clove Cigarettes (2002), 177
application
Article 31(3)(a) of the VCLT, 177
authentic element of interpretation, 178
Doha Declaration, 215–19
relate either to the interpretation or
application of the treaty, 178
Subsequent practice, 168–228, 232, 351
accept tacitly, 180
Article 31(3)(b) of the VCLT, 179–81
authentic element of interpretation, 179

Canada – Pharmaceutical Patents (2000), 227
canonical meaning of the provision, 181
common understanding of all the parties, 181
concordant, common and consistent, 180
EC – Chicken Cuts (2005), 179–80
imply agreement on the interpretation, 180
Japan – Alcoholic Beverages (1996), 180
lack of reaction, 181
US – Gambling (2005), 180
US – Section 101(5) Copyright Act (2000), 227

Sufficient manufacturing capacities, 299, 407
Supplementary means of interpretation, 162, 187, 191
ambiguous or obscure, 187
Article 32 of the VCLT, 186
circumstances of the conclusion, 189–90
confirming, 170
EC – Chicken Cuts (2005), 174
including, 191
The Canadian Cattlemen for Fair Trade
v. United States of America, 191
Japan – Alcoholic Beverages (1996), 187
judicial decisions, 191
manifestly absurd or unreasonable, 187
may, 188
means to aid an interpretation, 187
preparatory work, 188–89
subsidiary, 187
teachings of publicists, 191
Sustainable development, 12, 90, 193–97, 202, 214, 270, 351, 393
definition, 198
international customary law, 202
legal status, 197
Gabeškovo-Nagyamaros Project, 199
give effect to, 197
overarching objective of the WTO, 196
US – Shrimp (1998), 197
mutually reinforcing pillars, 199
objective of the WTO, 197
Preamble to the Marrakesh Agreement, 193
principle of integration and reconciliation, 198
Sustainable development objective, 231, 235,
273, 288, 308, 324, 344, 346, 350
Switzerland, 51, 72, 142

Take account of
EC – Approval and Marketing of Biotech
Products (2006), 204
US – Clove Cigarettes (2011), 294
Index

TBT, 294
   Article 12.3, 294
Technical effect, 267
Technological capabilities, 21, 79, 235, 251, 304
Technological capacities, 20, 22, 37, 56, 70, 139–39
Technology
dictionary meaning, 13
what the term “technology” means, 13
Technology Executive Committee, 94–95
Technology Mechanism, 94–95
Technology transfer
and technology dissemination (diffusion), 17
Channels, 18–25
FDI, 19
Initiation, 22
Licensing, 19–20
Reverse engineering, 23–25
Trade, 21–22
Definition, 16–18
Foray (2009), 17
IPCC, 16
World Intellectual Property Organisation
(WIPO), 16
direction of international technology
transfer, 41–42
market-based channels, 365
mechanisms, 92–94
not taken place at a scale large enough, 3
part of the bargain, 74
provisions
very little actual and effective
implementation, 2
provisions that govern or facilitate, 74–78
UNCTAD Draft International Code of
Conduct on the Transfer of
Technology, 13
Technology transfer and IPRs
Bali Road Map, 98
controversy, 96
international climate change regime,
96–106
Telecommunications industry, 146
Test data, 65, 114
Three-step test
Canad – Pharmaceutical Patents (2000),
262
comprehensive overall assessment, 264
cumulative basis, 262
limited exception, 262
unreasonably conflict with a normal
exploitation of the patent, 267
unreasonably prejudice the legitimate
interests, 268
US – Section 110 (5) Copyright Act (2000),
263
Trade restrictive, 255
Trade secret law, 117
Trade secrets, 65, 114–18, 121, 130, 149
a manner contrary to honest commercial
practices, 116
bad faith, 116
Footnote 10 to Article 39.2 of TRIPS, 116
subjective standard of analysis, 116
Article 1.2 of TRIPS, 115
Article 39.1 of TRIPS, 114
Article 39.2 of TRIPS, 116
duty to protect confidential information, 116
indefinitely, 117
information lawfully within their control, 115
non-disclosure nature, 118
reverse engineering, 117
role, 118
Transfer of ESTs, 78
Bali Action Plan, 91–92
clauses, 83
commitments, 82–85
Article 4.5 of the UNFCCC, 83
Kyoto Protocol, 87
Transition period, 45, 224
Transitional periods, 68, 78, 234
staggered implementing periods, 220
Travaux préparatoires, 187, 240
Treaty interpretation, 161, 323, 356
a holistic exercise, 163
authoritative interpretation, 217
textual interpretation, 174
evolving interpretations, 215
good faith interpretation, 289, 328
inherent limitations, 170
not a rigid sequence of discrete steps, 163
primary, obligatory sources of, 244
textual approach, 170
contextual, systemic and teleological
methodologies, 164
US – Continuedゼニング (2009)
a holistic exercise, 163
TRIPS
adoption of, 45
Article 1.1, 65
Article 1.1, first sentence, 328
Article 13, 260
Article 21, 297
Article 27
boundaries to patentability, 256
TRIPS (cont.)
Article 27.1, 112, 286, 352, 354
field of technology, 240
first sentence, 240
non-discrimination ... proper relationship of means and ends,
210
consistency requirement, 210–11

Index

Article 40.1, 326, 329
adverse effects on trade and technology transfer, 327
affirmative obligation, 328
non-binding “chapeau”, 327
obligation to regulate, 327
restrain competition, 327
Article 40.2, 326, 329–30, 332, 334
an adverse effect on competition, 332
coercive package licensing, 335
conditions preventing challenges to validity, 335
effect on competition, 333
exclusive grantback conditions, 335
first sentence, 330
include, 335
IPR-specific anti-competitive practices, 333
particular cases, 333
rule of reason, 333
second sentence, 334
Article 40.3 and 40.4, 326
Article 41.1, 319
Article 48.1, 318
Article 6, 353
Article 61, 114
Article 64, 67
Article 66.2, 2, 74–77, 156
implementation of, 77
negotiating history, 75
shall, 75
the effect of, 76
Article 67, 345, 357
technical and financial cooperation, 336
Article 7.2, 74, 205–7, 255, 308, 328
“should” provision, 206
a balance of rights and obligations, 206
Canada – Pharmaceutical Patents (2000), 207
Doha Declaration, 206
in mutually beneficial ways, 206
operational, 120
promote innovation and transfer and the dissemination of technology, 206
the overall goal of promoting social and economic welfare, 207
Article 8, 290
public interest principle, 308
Article 8.1, 207–11, 321
a proper relationship of means and ends, 210
consistency requirement, 210–11
Index

consistent with, 208
measures to promote public interest, 208
necessary, 208–10
proportionality of measures, 210
protection of public health and nutrition, 208
public interest in ESTs sectors, 211
public interest principle, 208
socio-economic and technology development, 208
weighing and balancing, 210
Article 8.2, 312, 327, 343, 354
abuse of IP rights, 316
adversely affect the international transfer of technology, 333
appropriate measures, 315, 325
Basic Principle, 314–22
consistency requirement, 315, 322–24
interpretive function, 315
overarching, constitutional principle, 314
policy statement, 314
practices which unreasonably restrain trade, 320
Articles 28 and 33, 256
Articles 30 and 31, 281
Articles 40.1 and 40.2, 335
Articles 7 and 8, 235, 257, 266, 270, 273, 297, 324, 329, 331, 344, 351
balancing objective and purpose, 205
balancing objectives, 213
Canada – Pharmaceutical Patents (2000), 212
Doha Ministerial Declaration, 212
interpretative role, 213
objective clues, 213
shall guide the interpretation, 198
Articles 8.2 and 40, 60, 312
balanced nature, 207
balancing objective, 222, 350
centrepiece of the global system of rules, 49
costs and benefits, 71
emergence, 60
“A” texts, 63
“B” texts, 64
forum shifting, 61
Footnote 6, 275
Footnote to Article 31
other use, 281
general purpose, 119
history of negotiations of the treaties incorporated into the TRIPS, 190
Canada – Pharmaceutical Patents (2000), 190
inconsistent with, 328
incorporating the Paris Convention, 112
mandating effective domestic IP rights enforcement, 119
minimum standards agreement, 65
most comprehensive multilateral agreement on IP, 60
negotiating history, 190, 286, 324
object and purpose, 203–5, 214, 268, 343
objective and purpose, 346
Paris-plus treaty, 113
Part II of TRIPS, 110, 326
Preamble, 204, 324, 344
reduce distortions and impediments to international trade, 320
Section 8
Control of Anti-competitive Practices in Contractual Licences, 326
spirit and purpose, 224
technology transfer-oriented provisions, 74–78
third pillar of the WTO Agreement (Annex 1C), 64
TRIPS amendment, 256, 299
TRIPS Council, 73, 76, 212, 217, 220–21, 224, 235, 363, 365
availability, sufficiency and effectiveness, 214
limits to patents, 159
pro-competitive measures, 159
TRIPS negotiations, 160, 280–81, 283–84, 334
TRIPS negotiators, 77, 206, 268, 271, 275
TRIPS-plus provisions, 4, 68, 72–74, 98
UK Commission on Intellectual Property Rights, 142, 231
UK Patents Act of 1883, 282
UNCED, 14, 49, 96
UNCLOS, 83–84
Uncompensated spillovers, 27
UNCTAD, 57, 59
UNCTAD Report (1974), 52
UNCTAD TOT Code of Conduct
“regulatory” approach to technology transfer, 56
major characteristics, 55
restrictive business practices, 57–59
UNGA resolution 32/159 of December 1976,
57
Undisclosed information, 65, 111, 114–116
UNDP Human Development Report (2001), 298
UNDP Human Development Report (2007),
316
Unfair competition law, 131
protection of undisclosed information, 116
UNFCCC, 94, 96, 234, 358
Article 11.1, 84
Article 2, 11
Article 3.1, 80–81
Article 4.1, 82
Article 4.1(c), 2, 15
Article 4.3, 84
Article 4.5 and 4.5, 106
Article 4.5, 2, 83, 232, 236, 260, 273, 331
as appropriate, 85
EST transfer commitments, 352
take all practicable steps, 84, 155
Article 4.7, 82, 85–87
implementation, 85
negotiations, 98, 305
Unilateral abuses of IPRs, 140
Unilateral trade sanctions, 65
United States, 33, 35–36, 39, 43–44, 48, 53–55,
61, 70, 72, 135, 141, 154, 244
American Clean Energy and Security Act, 102
Atomic Energy Act, 282
Foreign Relations Authorization Bill, 102
U.S. – Lead and Bismuth (1994), 165
United States’ Constitution, 31
US – Anti-Dumping and Countervailing
Duties (2011), 183
US – Carbon Steel (2002), 189
US – Chile FTA, 72
US – Clove Cigarettes (2011), 294
US – Clove Cigarettes (2012), 177
US – Continued Zeroing (2009), 163
US – Gambling (2005), 180
US – Jordan FTA, 73
US - Morocco FTA, 73
US – Section 101(5) Copyright Act (2000),
175, 263
US – Section 110(5) Copyright Act (2000),
227, 319
US – Section 301 (1999), 164
US – Shrimp (1998), 182, 193, 195, 197, 201,
226, 231, 310
US – Underwear (1997), 169
US antitrust law, 334
US Atomic Energy Act, 292
US Clean Air Act, 283–85, 290, 292
US Free Trade Agreement Implementation
Bill 2004, 242
US House of Representatives, 4, 102
US Patent Act, 244
US Patent and Trademark Office (USPTO),
251
US patent law, 248–49
US Supreme Court, 118, 317
Bonito Boats, Inc. v. Thunder Craft Boats,
Inc, 128
US-Bahrain FTA, 73
US-Section 211 Appropriations Act (2002), 67
Unreasonable, 154, 165, 207, 317, 319, 325, 344,
364
US – Section 110(5) Copyright Act (2000),
319
Unreasonably restrain trade
‘balancing’ test, 319
UNU-MERIT, 90
Uruguay Round negotiations, 49, 64, 190, 280,
312
Utility models, 35, 308, 352
Vagueness, 234
Voluntary licence, 290, 300, 338
Voluntary licensing, 304, 362
Waiver, 298, 306–7, 356
Waxman-Markey Bill, 102
Weighing and balancing, 210, 255, 334
Weighing of the competing interest, 319
Western European Countries, 72
Wind turbine, 149–50, 307
WIPO, 53, 55, 61, 63, 118, 120, 227, 248
WIPO Diplomatic Conference on the
Revision of the Paris Convention, 53
WIPO Document SCP/157/3, 237
WIPO Model Law for Developing
Countries on Inventions, 247
WIPO Patent Landscape Report on
Ritonavir, 146
WIPO treaties, 61, 118
Index

World Bank, 20, 41, 44, 71, 84, 251
World trading system, 68–69, 160, 195
World War II, 23, 51
WTO Agreement, 215, 231, 324
WTO Committee on Trade and Environment, 195, 234
WTO dispute settlement, 67, 275
WTO Dispute Settlement Body, 203
WTO dispute settlement system, 160
WTO panels, 172, 175, 187, 192, 245

© in this web service Cambridge University Press
www.cambridge.org